- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02548936
Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE
Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy in Reduction of Progression of Atherosclerosis Among Patients With Systemic Lupus Erythematosus: A Randomized Single-Blind Trial
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Patient Registries: A convenient consecutive sampling was used to recruit participants from outpatients in department of rheumatism of PUMCH. Prior to their enrollment in the study, all patients gave written, informed consent. To minimize subject non-response or rejection, the investigators inform patients the benefits and risks, and feedback them all physical examination results for free in the recruit period.
Randomization: A randomization will be used to allocate patients into Lipid-lowering treatment group and control group.
Blind: A trained ultrasonographer who assessed carotid intima media thickness (CIMT) (at baseline and 12 months) will be blinded to all clinical and treatment information.
Statistical analysis: The characteristics of the study sample were summarized using descriptive statistics with dichotomous or ordinal data presented as percentages and continuous data as means, standard deviations, and medians, interquartile range. Differences of progression rate of atherosclerosis between intervention group and control group were assessed with either the t test or the non-parametric Wilcoxon test. A multivariable linear regression model will be used to evaluate the relationship between the progression of CIMT and intervention after controlling for confounding factors. Statistical significance was defined as a 2-tailed P value less than 0.05. All calculations were performed using SAS version 9.3.
Quality Control and Data Management: Two doctors (not the main investigator) who come from department of cardiology with the experiences of clinical trial and a data manager will be serving as Data and Safety Monitor. A monthly meeting will be set up for investigators and monitors. The monitors need to review the study protocol and set Data Safety Management plan before recruitment. Then, they need to review rates of recruitment, adherence, follow-up conditions and assess the efficacy and harm during the study. If Monitors find that the simvastatin-ezetimibe combination therapy is causing severe adverse event, then a detailed record is needed. Monitors need to inform the main investigator within 3 hours and to inform state China Food and Drug Administration within 24 hours. Interim monitoring will focus on data quality, percentage of AE or SAE, and evidence of benefit.
Studietype
Registrering (Faktiske)
Fase
- Tidlig fase 1
Kontakter og plasseringer
Studiesteder
-
-
Beijing
-
Beijing, Beijing, Kina, 100730
- Peking Union Medical College Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- age ≥18 years and clinical diagnosis of SLE
- abnormal CIMT (≥0.9 mm at any site) by B-mode ultrasound
- LDL-C≥100mg/dl
- a signed written informed consent was able to be obtained.
Exclusion Criteria:
- atherosclerotic cardiovascular disease
- diabetes
- history of intolerance or allergy to the statins or ezetimibe
- had ever received statins or ezetimibe within 12 months of study entry
- LDL-C≥190mg/dl
- active infection
- ALT was higher than 2 times of the upper normal limit or CK was higher than 1.5 times of the upper normal limit.
- pregnant or lactating women
- patients with severe SLE.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Lipid-lowering treatment
The Lipid-lowering treatment is Ezetimibe+Simvastatin Drug Combination by oral administration.
The patients in intervention group received simvastatin (10mg/day) + ezetimibe (20 mg/day) combined therapy for 12 month.
|
The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
Andre navn:
|
Ingen inngripen: No lipid-lowering treatment
Without any Lipid-lowering treatment for 12 month.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The change of carotid intima media thickness over 12 months
Tidsramme: baseline, 12 months
|
CIMT(Unit: millimeter) is defined as the distance between the lumen-intima interface and the media-adventitia interface, which corresponded to the inner and outer echogenic lines seen on the B-mode ultrasound image.
|
baseline, 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The rate of abnormal elevated alanine aminotransferase (ALT)
Tidsramme: 1 month
|
ALT >40U/L
|
1 month
|
The rate of abnormal elevated alanine aminotransferase
Tidsramme: 3 months
|
ALT >40U/L
|
3 months
|
The rate of abnormal elevated alanine aminotransferase
Tidsramme: 6 months
|
ALT >40U/L
|
6 months
|
The rate of abnormal elevated alanine aminotransferase
Tidsramme: 12 months
|
ALT >40U/L
|
12 months
|
The rate of abnormal elevated creatine kinase (CK)
Tidsramme: 1 month
|
CK >60U/L
|
1 month
|
The rate of abnormal elevated creatine kinase
Tidsramme: 3 month
|
CK >60U/L
|
3 month
|
The rate of abnormal elevated creatine kinase
Tidsramme: 6 month
|
CK >60U/L
|
6 month
|
The rate of abnormal elevated creatine kinase
Tidsramme: 12 month
|
CK >60U/L
|
12 month
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Shuyang Zhang, MD, Peking Union Medical College Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Arteriosklerose
- Arterielle okklusive sykdommer
- Aterosklerose
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antimetabolitter
- Antikolesteremiske midler
- Hypolipidemiske midler
- Lipidregulerende midler
- Hydroksymetylglutaryl-CoA-reduktasehemmere
- Simvastatin
- Ezetimibe
- Ezetimib, Simvastatin medikamentkombinasjon
Andre studie-ID-numre
- pumch-sleas
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Ezetimibe+Simvastatin Drug Combination
-
Organon and CoFullført
-
Organon and CoFullførtHjerteinfarkt | Hyperkolesterolemi
-
Hue University of Medicine and PharmacyUniversità degli Studi di SassariUkjentKroniske nyresykdommer | HyperkolesterolemiVietnam
-
University of Sao PauloFullførtKoronar hjertesykdom
-
University of Maryland, BaltimoreMerck Sharp & Dohme LLCFullførtMetabolsk syndromForente stater
-
Organon and CoSchering-PloughFullførtKoronar sykdom | Hyperkolesterolemi
-
Organon and CoMerck Sharp & Dohme LLC; Schering-PloughFullført
-
Organon and CoFullført
-
National Cheng-Kung University HospitalFullført
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) og andre samarbeidspartnereFullførtDyslipidemi | Type 1 diabetes mellitusForente stater